Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y₁₂ Inhibitor Prescribing.

ABSTRACT: P2Y₁₂ inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend alternative P2Y₁₂ inhibitors for patients with decreased CYP2C19 function who had undergone percutaneous coronary intervention (PCI). The objective of this study was to evaluate prescriber response to these CDS alerts. Utilizing alert response data and P2Y₁₂ inhibitor prescriptions from October 2020 to December 2023, we evaluated prescriber response for 362 patients who had a mean of 2.2 (SD: 1.7) CYP2C19-clopidogrel a

SUBMITTER: Springer AN 

PROVIDER: S-EPMC12272324 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature